Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer

被引:38
作者
Choi, Ji-Yeob
Lee, Kyoung-Mu
Noh, Dong-Young
Ahn, Sei-Hyun
Lee, Jong-Eun
Han, Wonshik
Jang, In-Jin
Shin, Sang-Goo
Yoo, Keun-Young
Hayes, Richard B.
Kang, Daehee
机构
[1] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul 110799, South Korea
[2] Roswell Pk Canc Inst, Dept Epidemiol, Buffalo, NY 14263 USA
[3] NCI, Occupat & Environm Epidemiol Branch, Bethesda, MD 20892 USA
[4] Seoul Natl Univ, Coll Med, Dept Gen Surg, Seoul 110799, South Korea
[5] Univ Ulsan, Coll Med, Dept Gen Surg, Seoul, South Korea
[6] DNA Link Inc, Seoul, South Korea
[7] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea
[8] Seoul Natl Univ, Coll Med, Dept Canc Res Inst, Seoul 110799, South Korea
关键词
eNOS; breast cancer; survival; estrogen receptor;
D O I
10.1007/s10549-006-9245-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The endothelial cell-specific form of nitric oxide synthase (eNOS) may play an important role in tumor progression via angiogenesis or apoptosis. We studied eNOS -786T > C and 894G > T (Glu298Asp), two functionally significant SNPs, in relation to hazard of breast cancer recurrence or death in 873 women with incident, non-metastatic breast cancer, recruited from two teaching hospitals in Seoul, Korea, 1995-2002. Hazards were estimated by Cox proportional hazard models, in relation to genotype, adjusting for hormone receptor status, lymph node involvement, and tumor size. Women carriers of the eNOS -786C allele had significantly increased hazards of breast cancer recurrence or death, compared with women having the TT genotype (HR = 2.1, 95% CI = 1.03-4.33); risks increased up to 3-fold in ER positive cases (HR = 3.2, 95% CI = 0.95-10.50). The hazard was also increased in eNOS 894T carriers, however, it did not reach statistical significance (HR = 1.8, 95% CI = 0.85-3.93). The combined genotypes containing -786C or 894T was associated with a 2.5-fold risk, compared to the TT-GG genotypes, the most dominant genotype combination (95% CI = 1.29-4.68), with the greatest risks in ER positive cases (HR = 4.9, 95% CI = 1.31-18.36). These results indicate that the eNOS -786C polymorphism, and possibly the 894T polymorphism, are associated with breast cancer recurrence and death, particularly in women with ER positive tumors.
引用
收藏
页码:213 / 218
页数:6
相关论文
共 20 条
[1]
Simultaneous selection of the wild-type genotypes of the G894T and 4B/4A polymorphisms of NOS3 associate with high-altitude adaptation [J].
Ahsan, A ;
Norboo, T ;
Baig, MA ;
Pasha, MAQ .
ANNALS OF HUMAN GENETICS, 2005, 69 :260-267
[2]
Amoli MM, 2003, J RHEUMATOL, V30, P2019
[3]
Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer [J].
Choi, JY ;
Lee, KM ;
Park, SK ;
Noh, DY ;
Ahn, SH ;
Chung, HW ;
Han, W ;
Kim, JS ;
Shin, SG ;
Jang, IJ ;
Yoo, KY ;
Hirvonen, A ;
Kang, D .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (05) :1090-1095
[4]
Vascular invasion in human breast cancer is correlated to T → 786C polymorphism of NOS3 gene [J].
Ghilardi, G ;
Biondi, ML ;
Cecchini, F ;
DeMonti, M ;
Guagnellini, E ;
Scorza, R .
NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2003, 9 (02) :118-122
[5]
A haplotype analysis of HER-2 gene polymorphisms:: Association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea [J].
Han, W ;
Kang, D ;
Lee, JE ;
Park, IA ;
Choi, JY ;
Lee, KM ;
Bae, JY ;
Kim, S ;
Shin, ES ;
Lee, JE ;
Shin, HJ ;
Kim, SW ;
Kim, SW ;
Noh, DY .
CLINICAL CANCER RESEARCH, 2005, 11 (13) :4775-4782
[6]
Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer [J].
Hefler, LA ;
Ludwig, E ;
Lampe, D ;
Zeillinger, R ;
Leodolter, S ;
Gitsch, G ;
Koelbl, H ;
Tempfer, CB .
GYNECOLOGIC ONCOLOGY, 2002, 86 (02) :134-137
[7]
Tumor cell-derived nitric oxide is involved in the immune-rejection of an immunogenic murine lymphoma [J].
Hu, DE ;
Dyke, SOM ;
Moore, AM ;
Thomsen, LL ;
Brindle, KM .
CANCER RESEARCH, 2004, 64 (01) :152-161
[8]
Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase [J].
Jadeski, LC ;
Chakraborty, C ;
Lala, PK .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (04) :496-504
[9]
Augmented endothelial nitric oxide synthase (eNOS) protein expression in human pregnant myometrium:: possible involvement of eNOS promoter activation by estrogen via both estrogen receptor (ER)α and ERβ [J].
Kakui, K ;
Itoh, H ;
Sagawa, N ;
Yura, S ;
Korita, D ;
Takemura, M ;
Miyamaoto, Y ;
Saito, Y ;
Nakao, K ;
Fujii, S .
MOLECULAR HUMAN REPRODUCTION, 2004, 10 (02) :115-122
[10]
Endothelial nitric oxide synthase: Correlation with histologic grade, lymph node status and estrogen receptor expression in human breast cancer [J].
Martin, JHJ ;
Begum, S ;
Alalami, O ;
Harrison, A ;
Scott, KWM .
TUMOR BIOLOGY, 2000, 21 (02) :90-97